Musella Foundation Webinar Series: This Sunday Dr Brem is one of my all time favorite brain tumor doctors and is up to date and involved in the latest high tech treatments for brain tumors. Should be a great webinar!
EF-19 - A post-approval registry study of TTFields for the treatment of recurrent glioblastoma (GBM) This study shows a small improvement with Optune by itself compared to standard treatments. Enough to show Optune does have a positive effect but not enough to use Optune by itself for recurrent Glioblastoma (or to use the standard treatments either). Further study is needed combining Optune with other treatments to make meaningful gains in survival.
A Phase II Randomized, Multicenter, Open-Label Trial of Continuing Adjuvant Temozolomide Beyond Six Cycles in Patients With Glioblastoma (GEINO 14-01) As far as I know this is the first well designed trial to test if 6 or 12 months of Temodar is better. They said 6 months is better. The outcome is the same but the side effects are significantly worse in the 12 month group.
There have been previous reports saying the opposite but they were poorly designed retrospective studies that did not take into account people who stopped at 6 months did so because they weren't doing as well those who chose to continue to 12 months. The current study took people doing well at the end of the 6 months and randomized them so half got 6 additional months and half stopped at 6 months.
